These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 29975110

  • 1. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E, Cho KH, Harris ST, Flindt NR, Watt RK, Pai AB.
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [Abstract] [Full Text] [Related]

  • 3. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S, PHI112844 Investigators.
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT, Hiremath S, Jun M, Green SC, Wheeler DC, Coyne DW, Perkovic V, Badve SV.
    NEJM Evid; 2024 Sep; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [Abstract] [Full Text] [Related]

  • 7. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S, Tanaka T, Nangaku M.
    Rinsho Ketsueki; 2021 Sep; 62(5):371-377. PubMed ID: 34108317
    [Abstract] [Full Text] [Related]

  • 8. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H, Cheng Q, Wang J, Zhao X, Zhu S.
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [Abstract] [Full Text] [Related]

  • 9. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR.
    Am J Nephrol; 2021 Aug; 52(6):450-466. PubMed ID: 34280923
    [Abstract] [Full Text] [Related]

  • 10. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis.
    Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X.
    Front Endocrinol (Lausanne); 2023 Aug; 14():1131516. PubMed ID: 37008953
    [Abstract] [Full Text] [Related]

  • 11. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M, Tanaka T, Nangaku M.
    Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
    [Abstract] [Full Text] [Related]

  • 12. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, Bernhardt T.
    Nephron; 2019 Nov; 143(4):243-254. PubMed ID: 31387097
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
    Rawee P, Eisenga MF.
    Ned Tijdschr Geneeskd; 2023 Sep 28; 167():. PubMed ID: 37823872
    [Abstract] [Full Text] [Related]

  • 15. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Curr Opin Nephrol Hypertens; 2020 Jul 28; 29(4):414-422. PubMed ID: 32452915
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D, Macdougall IC.
    Pediatr Nephrol; 2019 Mar 28; 34(3):365-378. PubMed ID: 29569190
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia inducible factor-prolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials.
    Mohamed MMG, Oyenuga M, Shaikh S, Oyenuga A, Kheiri B, Nwankwo C.
    Int Urol Nephrol; 2023 Jan 28; 55(1):167-171. PubMed ID: 35852713
    [Abstract] [Full Text] [Related]

  • 19. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M, Sudchada P.
    Int Urol Nephrol; 2021 Feb 28; 53(2):283-290. PubMed ID: 32770437
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S, Guo J, Xie S, Chen J, Yu S, Yu Y.
    Int Urol Nephrol; 2021 Jun 28; 53(6):1139-1147. PubMed ID: 33026571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.